OKN-007 Alters Protein Expression Profiles in High-Grade Gliomas: Mass Spectral Analysis of Blood Sera

OKN-007 Alters Protein Expression Profiles in High-Grade Gliomas: Mass Spectral Analysis of Blood Sera

Current therapies for high-grade gliomas, particularly glioblastomas (GBM), do not extend patient survival beyond 16–22 months. OKN-007 (OKlahoma Nitrone 007), which is currently in phase II (multi-institutional) clinical trials for GBM patients, and has demonstrated efficacy in several rodent and h...

Full description

Bibliographic Details
Main Authors: Rheal A. Towner, James Hocker, Nataliya Smith, Debra Saunders, James Battiste, Jay Hanas
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Brain Sciences
Subjects:
OKN-007
high-grade-glioma
rat
blood sera
mass spectrometry (MS)
protein profiles
Online Access:https://www.mdpi.com/2076-3425/12/1/100

Internet

https://www.mdpi.com/2076-3425/12/1/100

Similar Items